Theravance Biopharma
TBPH
98 hedge funds and large institutions have $1.4B invested in Theravance Biopharma in 2016 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 16 reducing their positions, and 22 closing their positions.
163% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 16
142% more call options, than puts
Call options by funds: $1.8M | Put options by funds: $744K
84.36% more ownership
Funds ownership: 0% → 84.36% (+84%)
10% more capital invested
Capital invested by funds: $1.27B → $1.4B (+$124M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 22
2% less funds holding
Funds holding: 100 → 98 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$59.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$47.7M |
| 3 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$34.1M |
| 4 |
First Manhattan
New York
|
+$24.7M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.92M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$4.14M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.89M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.15M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$2.07M |
TBPH Hedge Fund Activity: Q4 2016 in Review
98 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2016, worth a combined $1.4B — up 9.7% from $1.27B a quarter earlier.
Fund positioning in TBPH was balanced in Q4 2016: 22 funds opened new positions, 22 closed out, 42 added to existing stakes and 16 trimmed.
The largest buyer was Baupost Group, adding an estimated $59.6M. The largest seller was Wellington Management Group, exiting entirely with an estimated $6.92M sold.
- 98 institutional investors held Theravance Biopharma (TBPH) as of Q4 2016, down from 100 in Q3 2016.
- Funds reported $1.4B of Theravance Biopharma stock for Q4 2016, up 9.7% quarter-over-quarter.
- 22 funds opened new Theravance Biopharma positions in Q4 2016 and 22 closed out, a net change of 0 holders.
- The largest Theravance Biopharma buyer in Q4 2016 was Baupost Group, an estimated $59.6M added.
- The largest Theravance Biopharma seller in Q4 2016 was Wellington Management Group, an estimated $6.92M sold.
Based on aggregated 13F filings for Q4 2016.